The US FDA has approved a new combination of immunotherapies for use together with platinum-based chemotherapy for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) whose tumors do not have EGFR mutations or ALK aberrations. The new combination comprises two drugs that act at different immune checkpoints: the CTLA-4 inhibitor tremelimumab (Imudo) and the anti-PDL1 antibody durvalumab (Imfinzi). This combination was recently approved for the first time for use in liver cancer, and durvalumab is already approved for use in lung cancer, bladder cancer, and biliary tract cancers.